Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
446.00    -1.50 (-0.34%)
Bid:
445.00
Ask:
450.00
Spread: 5.00 (1.124%)
Market Cap: £219.35m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Trading Update

1 Nov 2018 07:00

RNS Number : 9276F
Zotefoams PLC
01 November 2018
 

 

Zotefoams plc

("Zotefoams" or "the Group")

 

Trading Update

 

 

1st November 2018 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the third quarter ended 30 September 2018.

 

Zotefoams is pleased to report a record third quarter sales performance. Using foreign exchange rates as at 30 September 2018, full-year revenues and profit before tax are now expected to be slightly ahead of consensus market expectations.

 

In the nine months ended 30 September 2018, the Group has recorded:

 

· 16% increase in Group revenues against the comparative period, 18% in constant currency

· 7% growth in Polyolefin foams (72% of Group revenue)

o Improved sales mix

o Additional capacity contributing to 5% higher sales volumes;

· 97% increase in HPP sales (26% of Group revenue)

o Increased product adoption by end-users delivered very strong growth in our ZOTEK® PEBA elastomeric foams used in performance footwear;

o Strong recovery in ZOTEK® F fluoropolymer foams mainly from aviation applications;

o Orders for T-FIT® insulation products, down slightly year-to-date, are more strongly weighted in the final quarter this year, with annual growth in this product range dependent upon timing of shipments in the final quarter;

· MuCell Extrusion (2% of Group revenue)

o Year-to-date sales fell by 21%, excluding the one-off equipment sale in 2017;

o Q3 sales were impacted as a result of our internal restructuring, described in our interim results statement, which absorbed resource;

o MuCell Extrusion is being re-focused to develop the full potential of its technology;

· Capacity expansion programmes in the UK and USA are progressing well, with planned commissioning in 2019, while the announced new capacity in Poland is planned to come on stream in 2020.

 

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

"We expect 2018 to be another year of substantial progress for the Group: growing revenue, developing our portfolio of opportunities supported by committed capacity investments and enhancing our talent pool. We remain confident about the future prospects of the business."

 

 

- Ends -

 

 

 

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

IFC Advisory (PR)

+44 (0) 203 934 6630

Graham Herring

Miles Nolan

Zach Cohen

 

 

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. In addition, Zotefoams owns and licenses patented MuCell® microcellular foam technology, developed specifically for extrusion applications, from a base in Massachusetts, USA to customers worldwide.

 

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®). A third foam-manufacturing site, in Poland, is planned to begin operations in 2020.

 

www.zotefoams.com

 

AZOTE®, ZOTEK®, T-FIT® are registered trademarks of Zotefoams plc

MuCell® is a registered trademark of Trexel Inc.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTWGGBGUUPRGQG
Date   Source Headline
5th Jun 20172:14 pmRNSDirector/PDMR Shareholding
1st Jun 20174:30 pmRNSDirector/PDMR Shareholding
31st May 20177:00 amRNSDirector/PDMR Shareholding
17th May 20177:00 amRNSTrading Update
12th May 201711:16 amRNSDirector/PDMR Shareholding
12th Apr 20173:34 pmRNSAnnual Report and Accounts and Notice of 2017 AGM
12th Apr 20173:24 pmRNSDirector/PDMR Shareholding
12th Apr 20171:55 pmRNSHolding(s) in Company
10th Apr 20174:02 pmRNSDirector/PDMR Shareholding
6th Apr 20172:27 pmRNSHolding(s) in Company
6th Apr 20172:25 pmRNSHolding(s) in Company
28th Mar 201711:36 amRNSDirector/PDMR Shareholding
27th Mar 201710:16 amRNSHolding(s) in Company
24th Mar 20173:33 pmRNSHolding(s) in Company
23rd Mar 201710:11 amRNSHolding(s) in Company
22nd Mar 20173:28 pmRNSHolding(s) in Company
14th Mar 20175:28 pmRNSDirector/PDMR Shareholding
14th Mar 20177:00 amRNSFinal Results
9th Mar 20177:00 amRNSCoveris using MuCell® technology
15th Feb 201710:46 amRNSDirector/PDMR Shareholding
10th Feb 20177:00 amRNSHolding(s) in Company
1st Feb 20176:27 pmRNSHolding(s) in Company
12th Jan 20179:36 amRNSDirector/PDMR Shareholding
11th Jan 201710:33 amRNSHolding(s) in Company
10th Jan 20175:34 pmRNSHolding(s) in Company
9th Jan 20177:00 amRNSTrading Update
6th Jan 20177:00 amRNSAppointment of Joint Broker
6th Jan 20177:00 amRNSAcquires full ownership of its joint venture
22nd Dec 20164:35 pmRNSPrice Monitoring Extension
13th Dec 20161:58 pmRNSDirector/PDMR Shareholding
24th Nov 20167:00 amRNSHolding(s) in Company
15th Nov 201612:40 pmRNSDirector/PDMR Shareholding
14th Nov 201610:30 amRNSDirector Declaration
28th Oct 20167:00 amRNSThird Quarter Trading Update
25th Oct 20164:40 pmRNSSecond Price Monitoring Extn
25th Oct 20164:35 pmRNSPrice Monitoring Extension
24th Oct 201612:07 pmRNSSecond Price Monitoring Extn
24th Oct 201612:02 pmRNSPrice Monitoring Extension
20th Oct 20164:40 pmRNSSecond Price Monitoring Extn
20th Oct 20164:35 pmRNSPrice Monitoring Extension
19th Oct 20163:43 pmRNSHolding(s) in Company
18th Oct 201611:56 amRNSDirector/PDMR Shareholding
14th Oct 20164:35 pmRNSPrice Monitoring Extension
13th Oct 20164:35 pmRNSPrice Monitoring Extension
12th Oct 20165:56 pmRNSDirector/PDMR Shareholding
5th Oct 20164:29 pmRNSHolding(s) in Company
14th Sep 201611:16 amRNSDirector/PDMR Shareholding
23rd Aug 20164:40 pmRNSSecond Price Monitoring Extn
23rd Aug 20164:35 pmRNSPrice Monitoring Extension
12th Aug 20167:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.